(Q33373492)

26 July 2017

title

A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma (English)

1 reference

26 July 2017

0 references

J M G Larkin

1

1 reference

26 July 2017

S A Hughes

2

1 reference

26 July 2017

D A Beirne

3

1 reference

26 July 2017

P M Patel

4

1 reference

26 July 2017

I M Gibbens

5

1 reference

26 July 2017

S C Bate

6

1 reference

26 July 2017

K Thomas

7

1 reference

26 July 2017

T G Eisen

8

1 reference

26 July 2017

M E Gore

9

1 reference

26 July 2017

language of work or name

English

0 references

publication date

5 December 2006

1 reference

British Journal of Cancer

26 July 2017

published in

1 reference

26 July 2017

volume

96

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

44-48

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6603503

26 July 2017

exact match

0 references

cites work

Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360201

Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360201

A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360201

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360201

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360201

Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360201

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Gr

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360201

Fotemustine and dacarbazine plus recombinant interferon alpha 2a in thetreatment of advanced melanoma.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360201

Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360201

In vitro inactivation of human O6-alkylguanine DNA alkyltransferase by antitumor triazene compounds

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360201

Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360201

Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360201

A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360201

Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360201

Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study Group

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360201

Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360201

Fotemustine and DTIC combination in patients with disseminated malignant melanoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360201

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study

28 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603503

Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603503

Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603503

Activity and unexpected lung toxicity of the sequential administration of two alkylating agents--dacarbazine and fotemustine--in patients with melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603503

Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603503

Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603503

Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603503

Phase I study of temozolomide and lomustine in the treatment of high grade malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603503

Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603503

Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360201

Treatment of patients with metastatic melanoma with a one day regimen of dacarbazine, vincristine, bleomycin and lomustine plus interferon-alpha

31 October 2018

1 reference

12 December 2020

BOLD+interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy

1 reference

12 December 2020

Carmustine and streptozocin in refractory melanoma: an attempt at modulation of O-alkylguanine-DNA-alkyltransferase

1 reference

12 December 2020

Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine

1 reference

12 December 2020

The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

1 reference

12 December 2020

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6603503

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference

26 July 2017

1 reference